MedTrace Logo

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

NCT00732810 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2015-08-05

No results posted yet for this study

Summary

To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment. The standard treatment used is capecitabine for breast cancer and erlotinib for NSCLC. The study will also determine the activity of SCH 727965 treatment in participants who experience cancer progression after standard treatment.

Conditions

  • Breast Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

SCH 727965

SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.

DRUG

Capecitabine

Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.

DRUG

Erlotinib

Erlotinib 150 mg orally once daily until disease progression.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732810 on ClinicalTrials.gov